204 related articles for article (PubMed ID: 37030113)
1. Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries.
Post HC; Schutte T; van Oijen MGH; van Laarhoven HWM; Hollak CEM
ESMO Open; 2023 Apr; 8(2):101208. PubMed ID: 37030113
[TBL] [Abstract][Full Text] [Related]
2. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
3. Market access to new anticancer medicines for children and adolescents with cancer in Europe.
Schoot RA; Otth MA; Frederix GWJ; Leufkens HGM; Vassal G
Eur J Cancer; 2022 Apr; 165():146-153. PubMed ID: 35235871
[TBL] [Abstract][Full Text] [Related]
4. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
5. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
Iglesias-López C; Agustí A; Vallano A; Obach M
Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
[TBL] [Abstract][Full Text] [Related]
6. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
Ferrario A
Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
[TBL] [Abstract][Full Text] [Related]
7. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
[No Abstract] [Full Text] [Related]
8. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
[TBL] [Abstract][Full Text] [Related]
9. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A
Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334
[TBL] [Abstract][Full Text] [Related]
10. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
11. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
Kandolf Sekulovic L; Guo J; Agarwala S; Hauschild A; McArthur G; Cinat G; Wainstein A; Caglevic C; Lorigan P; Gogas H; Alvarez M; Duncombe R; Lebbe C; Peris K; Rutkowski P; Stratigos A; Forsea AM; De La Cruz Merino L; Kukushkina M; Dummer R; Hoeller C; Gorry C; Bastholt L; Herceg D; Neyns B; Vieira R; Arenberger P; Bylaite-Bucinskiene M; Babovic N; Banjin M; Putnik K; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Ymeri A; Stojkovski I; Garbe C
Eur J Cancer; 2018 Nov; 104():201-209. PubMed ID: 30388700
[TBL] [Abstract][Full Text] [Related]
12. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
Kleijnen S; Lipska I; Leonardo Alves T; Meijboom K; Elsada A; Vervölgyi V; d'Andon A; Timoney A; Leufkens HG; De Boer A; Goettsch WG
Ann Oncol; 2016 Sep; 27(9):1768-75. PubMed ID: 27329251
[TBL] [Abstract][Full Text] [Related]
13. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
14. Differences in time to patient access to innovative cancer medicines in six European countries.
Vancoppenolle JM; Franzen N; Koole SN; Retèl VP; van Harten WH
Int J Cancer; 2024 Mar; 154(5):886-894. PubMed ID: 37864395
[TBL] [Abstract][Full Text] [Related]
15. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
Akehurst RL; Abadie E; Renaudin N; Sarkozy F
Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
[TBL] [Abstract][Full Text] [Related]
16. Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit.
Hofmarcher T; Szilagyiova P; Gustafsson A; Dolezal T; Rutkowski P; Baxter C; Karamousouli E
ESMO Open; 2023 Aug; 8(4):101593. PubMed ID: 37413761
[TBL] [Abstract][Full Text] [Related]
17. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634
[TBL] [Abstract][Full Text] [Related]
18. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries.
Kamusheva M; Vassileva M; Savova A; Manova M; Petrova G
Front Public Health; 2018; 6():61. PubMed ID: 29556491
[TBL] [Abstract][Full Text] [Related]
19. The European Medicines Agency facilitates access to medicines in low- and middle-income countries.
Cavaller Bellaubi M; Harvey Allchurch M; Lagalice C; Saint-Raymond A
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):321-325. PubMed ID: 32053756
[No Abstract] [Full Text] [Related]
20. Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
Kingham R; Wheeler J
Food Drug Law J; 2009; 64(1):101-14. PubMed ID: 19998574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
